Wellbeing Digital Sciences Inc says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection letter'...